热门资讯> 正文

GT Biopharma在GTB-3650 1期剂量升级试验的队列3中开始给药，治疗复发性或难治性表达CD 33的血液恶性肿瘤，计划在完成额外剂量队列后于2025年晚些时候发布初始1期结果

2025-08-11 19:14

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.
The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。